Key Highlights
● Advanced Flower Capital closed at $3.01 on August 13, 2026, up roughly 6-7% for the session.
● The company, once known as AFC Gamma, spun off its Commercial Real Estate book as Sunrise Realty Trust in 2024.
● A Business Development Company pivot has driven NAV growth, a positive signal for the specialty lender's turnaround.
● Lingering Credit scars from the earlier cannabis-focused lending portfolio continue to weigh on the broader Investment narrative.
Advanced Flower Capital Inc. (NASDAQ: AFCG), the specialty lender once known as AFC Gamma before it spun off its commercial real estate book as Sunrise Realty Trust in 2024, closed at $3.01 on August 13, 2026, up roughly 6-7% for the session. The move came the same morning the company reported second-quarter results and disclosed that net asset value per share climbed to $8.25. AFCG converted from a Mortgage REIT into a business development company (BDC) on January 1, 2026, a structural shift meant to widen its lending mandate beyond cannabis operators even as legacy marijuana-sector loans continue to weigh on credit quality. The stock remains far below its historical dividend-paying heyday and trades at a steep discount to book value.
Latest Development
AFC released second-quarter 2026 results (for the period ended June 30, 2026) before market open on August 13. Total investment income came in at $8.7 million, down from $9.8 million in the first quarter, a decline management attributed largely to the non-recurrence of a $1.5 million exit fee booked earlier in the year but still ahead of analyst estimates. Net investment income was $3.5 million, or $0.15 per share. NAV per share rose $0.35 sequentially to $8.25, which the company attributed to net investment income generation, accretive share repurchases executed at a discount to book value, and unrealized appreciation across the portfolio. AFC also disclosed that its Sunburn Loan was returned to performing status after the borrower satisfied forbearance conditions, while the DMA dispensary-sale process advanced with two regulatory approvals and closings completed in July. market coverage tied the day's stock gain to the Revenue beat, the NAV increase, and accretive buybacks; no separate company-specific catalyst beyond the Earnings release itself has been independently verified.
What the Numbers Show
Net investment income of $0.15 per share provided roughly 3x coverage of the $0.05 quarterly Dividend declared for the period (paid July 15, 2026), a dividend that has been cut sharply from the $0.56 per share AFC Gamma paid quarterly back in 2022, underscoring how far the payout has been reset since the REIT-era cannabis lending boom. Total portfolio Fair Value stood at about $290 million across 17 portfolio companies, while total commitments reached $386 million (principal outstanding of $364 million) across 18 companies, with the portfolio fully invested in senior secured first-lien Debt (59% floating-rate, 41% fixed) yielding a weighted average of 13.2% in cash interest plus 1.3% payment-in-kind, excluding non-accruals. Credit quality remains the key overhang: internally rated "5" (impaired) positions represented about 22.7% of the portfolio by fair value, tied to three non-accrual borrowers, Debbie (DEBI), DMA, and Justice Grown. Justice Grown is in Maturity default and subject to foreclosure proceedings, while DEBI has a binding term sheet for a $12.5 million asset sale with management expecting to recover 78%-80% of proceeds. Debt-to-equity was 1.1x (0.53x net of cash), with an asset coverage ratio of 190%, cash of $106.5 million, and over $70 million of additional deployable liquidity.
Why Investors Are Paying Attention
AFCG sits at the intersection of two narratives: a private-credit lender trying to prove it can diversify away from a troubled niche, and a cannabis-adjacent name that could benefit if federal policy keeps shifting. On the regulatory front, the Justice Department and DEA in April 2026 moved FDA-approved and state-licensed medical Marijuana Products into Schedule III of the Controlled Substances Act and opened an expedited administrative hearing process, begun in late June 2026, to evaluate broader rescheduling from Schedule I to Schedule III. Management, however, was notably cautious on the Q2 call, with the CEO stating that "access to Equity capital in the cannabis industry" remains challenged despite the regulatory progress and recent cannabis-company uplistings to the NYSE, a dynamic that complicates refinancing Options for AFC's remaining cannabis borrowers. Meanwhile, the company has been actively repurchasing stock at prices well below NAV (roughly $3.29 per share on average in the quarter against an $8.25 book value), a discount some investors view as a value opportunity if credit losses stabilize.
Bull Case
Bulls point to a Book Value of $8.25 per share against a stock price near $3, implying the market is pricing in substantial further credit losses beyond what has already been marked down. The BDC conversion diversifies the lending base into new verticals, including a recent $7 million behavioral-health credit commitment, reducing single-sector concentration risk over time. Net investment income currently covers the dividend roughly threefold, leaving room for either distribution growth or continued NAV-accretive buybacks. Leverage is modest relative to BDC peers (net debt-to-equity of 0.53x versus a stated sector average near 1.3x), and the company reports a large, though unpredictable, $1.3 billion origination pipeline plus more than $70 million of near-term deployable capital.
Bear Case
The bear case centers on unresolved legacy cannabis credits: nearly a quarter of the portfolio by fair value is rated impaired, and Justice Grown's foreclosure proceeding carries real recovery uncertainty. The dividend has already been cut roughly 90% from 2022 levels, reflecting years of credit deterioration, and further markdowns could still occur. Total investment income actually declined quarter-over-quarter once a one-time fee is excluded, and management itself flagged that new originations will be "lumpy and episodic." Broader private-credit market stress, cited on the earnings call, adds macro risk on top of company-specific cannabis exposure, and the stock's deep discount to NAV may reflect informed skepticism rather than mispricing.
What Could Move the Stock Next?
Investors should watch resolution of the Justice Grown foreclosure and the DEBI asset sale, both likely to affect NAV in coming quarters; the outcome of the DEA's expedited Schedule I-to-III rescheduling hearing process; further BDC-diversification originations outside cannabis; the pace and pricing of ongoing share buybacks; and the company's next dividend declaration relative to net investment income coverage.
A Pivot That Hasn't Fully Erased the Past
Advanced Flower Capital's second-quarter print showed a lender in transition, book value rising, leverage conservative, and a Diversification strategy underway, but still carrying meaningful scars from its cannabis-lending roots, with nearly a quarter of its portfolio impaired. The wide gap between the $3.01 share price and $8.25 NAV per share captures that tension directly. Whether that gap closes likely depends on how cleanly management resolves its remaining non-accrual credits and how successfully the BDC pivot builds a more diversified, lower-risk lending book over the coming quarters.






Please wait processing your request...